DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20202022

Corona kills corona: convalescent sera option for global war against corona virus disease 2019

Babita ., Anita Punia, S. K. Jha, Mahavir Jangra

Abstract


On December 31st, 2019 China reported first case of atypical pneumonia in Wuhan, the capital of Hubei province. The causative virus was found to be a beta coronavirus, closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV-1) from 2003 and similar to Sarbeco viruses isolated from bats. It was therefore termed SARS-CoV-2 and the disease was named corona virus disease 2019 (COVID-19). The outbreak in Wuhan expanded quickly and led to the lockdown of Wuhan and other parts of China. While the lockdown, at least temporarily, brought the situation under control in China, but SARS-CoV-2 spread globally causing a pandemic with more than 4 lakh infections and about 19000 fatalities (as of March 25, 2020). Nucleic acid tests that detect the SARS-CoV-2 RNA genome were quickly developed and are now widely employed to diagnose COVID-19.


Keywords


COVID-19, Convalescent sera, Pandemic

Full Text:

PDF

References


Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;3:1-4.

Gorbalenya AE, Baker SC, Baric RS. The species Severe acute respiratory syndrome-related 291 coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;2:1-9.

Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem. 2020;66(4):549-55.

Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real time RT-PCR. Euro Surveill. 2020;25(3):2000045.

Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antivrial Res. 2000;47:57-77.

Lachmann PJ. The use of antibodies in the prophylaxis and treatment of infections. Emerg Microbes Infect. 2012;1:e11.

Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment. Ann Intern Med. 2006;145:599-609.

Huang IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447-56.

Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6.

Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562-9.

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3.

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020.

Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J of Med. 2007;8;357(19):1903-15.